IRLAB: Mesdopetam returning to IRLAB and additional clinical data presented - Redeye

Redeye comments on yesterday’s news that the rights to Mesdopetam have been returned to IRLAB. Furthermore, as the company now has the communication rights, IRLAB also shared more data from the phase IIb trial of the drug candidate in PD-LIDs.

Länk till analysen i sin helhet: https://www.redeye.se/research/936388/irlab-mesdopetam-returning-to-irlab-and-additional-clinical-data-presented?utm_source=finwire&utm_medium=RSS